Please enter the email address you used to register, then we will send you a link to choose a new password
WLDN: 21% | Willdan Group shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years.
GRFS: 20% | Grifols Said Compared To Consolidated Interim Financial Statements For 2023 Published On Feb 29, 2024, This Integration Does Not Impact The Income Statement, Nor Does It Have A Material Impact On Key Metrics
AMLX: -81% | Amylyx Pharmaceuticals Announced Topline Results From PHOENIX Phase 3 Trial Of AMX0035 For Amyotrophic Lateral Sclerosis, The Study Did Not Meet Its Primary Endpoint Nor Was There Statistical Significance Seen In Secondary Endpoints
Posted In: AMLX GRFS WLDN